Your browser doesn't support javascript.
loading
Thymic Epithelial Neoplasms: Focusing on the Epigenetic Alterations.
Psilopatis, Iason; Pergaris, Alexandros; Vrettou, Kleio; Theocharis, Stamatios; Troungos, Constantinos.
Afiliação
  • Psilopatis I; First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Street, Bld 10, Goudi, 11527 Athens, Greece.
  • Pergaris A; Charité-University School of Medicine, Augustenburger Pl. 1, 13353 Berlin, Germany.
  • Vrettou K; First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Street, Bld 10, Goudi, 11527 Athens, Greece.
  • Theocharis S; First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Street, Bld 10, Goudi, 11527 Athens, Greece.
  • Troungos C; First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Street, Bld 10, Goudi, 11527 Athens, Greece.
Int J Mol Sci ; 23(7)2022 Apr 06.
Article em En | MEDLINE | ID: mdl-35409405
ABSTRACT
Thymic Epithelial Neoplasms (TENs) represent the most common tumors of the thymus gland. Epigenetic alterations are generally involved in initiation and progression of various cancer entities. However, little is known about the role of epigenetic modifications in TENs. In order to identify relevant studies, a literature review was conducted using the MEDLINE and LIVIVO databases. The search terms thymoma, thymic carcinoma, thymic epithelial neoplasm, epigenetics, DNA methylation, HDAC and miRNA were employed and we were able to identify forty studies focused on TENs and published between 1997 and 2021. Aberrant epigenetic alterations seem to be involved in the tumorigenesis of thymomas and thymic carcinomas, with numerous studies reporting on non-coding RNA clusters and altered gene methylation as possible biomarkers in different types of TENs. Interestingly, Histone Deacetylase Inhibitors have shown potent antitumor effects in clinical trials, thus possibly representing effective epigenetic therapeutic agents in TENs. Additional studies in larger patient cohorts are, nevertheless, needed to verify the clinical utility and safety of novel epigenetic agents in the treatment of patients with TENs.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Timoma / Neoplasias do Timo / Neoplasias Epiteliais e Glandulares / MicroRNAs Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Timoma / Neoplasias do Timo / Neoplasias Epiteliais e Glandulares / MicroRNAs Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article